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CLARIFICATION OF MEDICAL POLICY 
FOR SKIN LESION REMOVAL 
The purpose of this communication is to clarify the reference to 
Efudex topical cream contained in our local medical review policy 
(LMRP) for skin lesion removal. This policy was published in the 
October, 1996 special edition of the "Medicare B Update!" 
The above referenced policy in no way circumvents physician 
judgment. The skin lesion LMRP simply seeks to articulate when 
excision or destruction (e.g., laser treatment, chemical treatments) is . . 
considered medically necessary. There are clinical criteria cited in the 
skin lesion LMRP that constitute appropriateness. Several of the 
criteria are: 
• When the patient presents with an actinic keratosis that has 
changed in size, has developed erythema, has thickened, has 
ulcerated, has ernded, has developed changes at the tumor 
margins, has become ·markedly hyperkeratotic, in which pain has 
developed and/or a cutaneous horn has develo_ped; 
• When the patient presents with an actinic keratosis of the 
lower-lip, upper-lip, conjunctivae, nose, ear, or eyelid; 
• When the patient presents with actinic keratosis and has a 
history· of one of the following: chronic immunosuppression, 
treatment of psoriasis with psoralen-ultrayiolet A (PUVA)' 
therapy, xeroderma pigmentosum, albinism, or · discoid lupus 
erythematosus, and/or previous treatment of a biopsy-proven 
Squamous Cell Carcinoma or other skin malignancy; 
• When a patient presents with a keratosis and has a history of 
significant exposure to therapeutic or occupational radiation 
therapy; 
• When the patient has multiple actinic keratoses and has self-
administered 2 % to 5 % Efudex topical cream for two to four 
weeks and the actinic keratoses have not responded to this 




There has been considerable misunderstanding of the reference to 
Efudex. A fundamental principal in the policy is that treatment of 
asymptomatic actinic keratosis is medically unnecessary. This would 
be true for any method of treatment, e.g., surgical, laser or cryogenic 
destruction, or use of topical creams_ (chemical destruction). Because 
literature indicates that lesions failing topical treatment with Efudex 
suggests a higher likelihood of malignancy, we have allowed for 
coverage in these cases. In other words, a failure of Efudex 
establishes a clinical criterion for a lesion being suspicious versus 
asymptomatic. 
In short, our skin lesion LMRP lays out the criteria for when the 
removal of skin lesions is approp.riate. The policy both reduces 
inappropriate billing and protects beneficiaries from unnecessary 
procedures. Should additional medical literature or other information 
relevant to this matter become available, providers are always free to 
contact us and request policy changes. In addition, we continue to 
offer formal appeal rights to providers who believe their claims were 
improperly denied. 
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